

Zoe Mario

List of Publications by Citations

Source: <https://exaly.com/author-pdf/632534/zoe-marino-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

2,215
citations

21
h-index

47
g-index

66
ext. papers

2,722
ext. citations

5.6
avg, IF

4.68
L-index

#	Paper	IF	Citations
60	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016 , 65, 719-726	13.4	709
59	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology</i> , 2017 , 153, 1273-1283.e1	13.3	164
58	Viral hepatitis in liver transplantation. <i>Gastroenterology</i> , 2012 , 142, 1373-1383.e1	13.3	156
57	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017 , 66, 1138-1148	13.4	131
56	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. <i>Hepatology</i> , 2018 , 67, 1683-1694	11.2	83
55	Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. <i>Journal of Hepatology</i> , 2020 , 72, 472-480	13.4	79
54	Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 575-583.e1	6.9	75
53	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. <i>Hepatology</i> , 2017 , 65, 1810-1822	11.2	64
52	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. <i>Seminars in Liver Disease</i> , 2017 , 37, 109-118	7.3	59
51	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2020 , 73, 1415-1424	13.4	55
50	Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. <i>Gastroenterology</i> , 2018 , 155, 311-315.e6	13.3	51
49	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019 , 70, 874-884	13.4	44
48	Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , 2018 , 69, 603-607	13.4	44
47	Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C. <i>American Journal of Transplantation</i> , 2014 , 14, 375-83	8.7	39
46	Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy. <i>PLoS ONE</i> , 2016 , 11, e0155094	3.7	38
45	Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. <i>Journal of Hepatology</i> , 2013 , 58, 415-20	13.4	37
44	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019 , 71, 666-672	13.4	35

43	Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 89-94	3.4	32
42	New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. <i>Gut</i> , 2014 , 63, 207-15	9.2	26
41	Hepatitis A outbreak in Barcelona among men who have sex with men (MSM), January-June 2017: A hospital perspective. <i>Liver International</i> , 2018 , 38, 588-593	7.9	25
40	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2021 ,	19.2	21
39	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020 , 174, 104694	10.8	20
38	Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1397-1408	6.1	19
37	HEV infection in two referral centers in Spain: epidemiology and clinical outcomes. <i>Journal of Clinical Virology</i> , 2015 , 63, 76-80	14.5	19
36	Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. <i>Journal of Gastroenterology</i> , 2013 , 48, 762-9	6.9	17
35	A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. <i>Scientific Reports</i> , 2017 , 7, 10497	4.9	16
34	Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2021 , 74, 1064-1074	13.4	15
33	Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 364-74	6.1	12
32	Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2014 , 61, 270-7	13.4	11
31	Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. <i>Liver International</i> , 2019 , 39, 826-834	7.9	11
30	Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. <i>Transplant Infectious Disease</i> , 2017 , 19, e12696	2.7	10
29	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017 , 37, 1823-1832	7.9	8
28	Incidence of depression in patients with hepatitis C treated with direct-acting antivirals. <i>Revista Brasileira De Psiquiatria</i> , 2020 , 42, 72-76	2.6	8
27	Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1570-1578	4	7
26	Systematic review with meta-analysis: neuroimaging in hepatitis C chronic infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1238-1252	6.1	7

25	Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1515-1525	3.4	7
24	Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. <i>Journal of Hepatology</i> , 2020 , 73, 1360-1367	13.4	7
23	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , 2016 , 65, 864-865	13.4	6
22	Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. <i>Digestive and Liver Disease</i> , 2014 , 46 Suppl 5, S197-205	3.3	6
21	Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015 , 21, 5421-6	5.6	5
20	Evaluation of a portable hemoglobinometer (HemoCue) to control anemia in hepatitis C liver transplant recipients undergoing antiviral therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2011 , 23, 942-7	2.2	5
19	Association of chronic inflammation and perceived stress with abnormal functional connectivity in brain areas involved with interoception in hepatitis C patients. <i>Brain, Behavior, and Immunity</i> , 2019 , 80, 204-218	16.6	4
18	Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy. <i>Frontiers in Immunology</i> , 2020 , 11, 129	8.4	4
17	Simple prediction of long-term clinical outcomes in patients with mild hepatitis C recurrence after liver transplantation. <i>Transplant International</i> , 2016 , 29, 698-706	3	4
16	Hepatitis C treatment for patients post liver transplant. <i>Current Opinion in Organ Transplantation</i> , 2015 , 20, 251-8	2.5	3
15	Advances in hepatitis C therapies. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1929-43	4	2
14	Low seroprevalence and zero incidence rate of hepatitis E in men who have sex with men during a hepatitis A outbreak. <i>Journal of Medical Virology</i> , 2020 , 92, 1359-1362	19.7	2
13	Improvement of sexuality after hepatitis C cure with direct acting antivirals. <i>Liver International</i> , 2020 , 40, 2972-2977	7.9	2
12	Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8 T cells after direct-acting antiviral therapies. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1408-1418	3.4	2
11	Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1019-1024	3.4	2
10	Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 968-973	6.1	2
9	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
8	Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut". <i>Journal of Hepatology</i> , 2020 , 72, 1036-1037	13.4	1

7	Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. <i>Liver International</i> , 2021 ,	7.9	1
6	Efficacy and safety of direct-acting antivirals in older patients with cirrhosis and high comorbidity index. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 389-394	2.2	0
5	Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. <i>Liver International</i> , 2021 , 41, 2733-2746	7.9	0
4	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response". <i>Journal of Hepatology</i> , 2019 , 71, 447-448	12.4	0
3	Considerations for optimizing Wilson's disease patients' long-term follow-up. <i>Gastroenterology & Hepatology (English Edition)</i> , 2022 , 45, 146-146	0.1	0
2	Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy. <i>Digestive and Liver Disease</i> , 2019 , 51, 875-881	3.3	0
1	The challenge of diagnosing Wilson's disease in patients with MAFLD. <i>Gastroenterology & Hepatology</i> , 2021 ,	0.9	0